Literature DB >> 19074902

Genome-wide allelic state analysis on flow-sorted tumor fractions provides an accurate measure of chromosomal aberrations.

Willem E Corver1, Anneke Middeldorp, Natalja T ter Haar, Ekaterina S Jordanova, Marjo van Puijenbroek, Ronald van Eijk, Cees J Cornelisse, Gert Jan Fleuren, Hans Morreau, Jan Oosting, Tom van Wezel.   

Abstract

Chromosomal aberrations are a common characteristic of cancer and are associated with copy number abnormalities and loss of heterozygosity (LOH). Tumor heterogeneity, low tumor cell percentage, and lack of knowledge of the DNA content impair the identification of these alterations especially in aneuploid tumors. To accurately detect allelic changes in carcinomas, we combined flow-sorting and single nucleotide polymorphism arrays. Cells derived from archival cervical and colon cancers were flow-sorted based on differential vimentin and keratin expression and DNA content and analyzed on single nucleotide polymorphism arrays. A new algorithm, the lesser allele intensity ratio, was used to generate a molecular measure of chromosomal aberrations for each case. Flow-sorting significantly improved the detection of copy number abnormalities; 31.8% showed an increase in amplitude and 23.2% were missed in the unsorted fraction, whereas 15.9% were detected but interpreted differently. Integration of the DNA index in the analysis enabled the identification of the allelic state of chromosomal aberrations, such as LOH ([A]), copy-neutral LOH ([AA]), balanced amplifications ([AABB]), and allelic imbalances ([AAB] or [AAAB], etc.). Chromosomal segments were sharply defined. Fluorescence in situ hybridization copy numbers, as well as the high similarity between the DNA index and the allelic state index, which is the average of the allelic states across the genome, validated the method. This new approach provides an individual molecular measure of chromosomal aberrations and will likely have repercussions for preoperative molecular staging, classification, and prognostic profiling of tumors, particularly for heterogeneous aneuploid tumors, and allows the study of the underlying molecular genetic mechanisms and clonal evolution of tumor subpopulations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074902     DOI: 10.1158/0008-5472.CAN-08-2665

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Tracing the tumor lineage.

Authors:  Nicholas E Navin; James Hicks
Journal:  Mol Oncol       Date:  2010-05-05       Impact factor: 6.603

2.  Inferring tumor progression from genomic heterogeneity.

Authors:  Nicholas Navin; Alexander Krasnitz; Linda Rodgers; Kerry Cook; Jennifer Meth; Jude Kendall; Michael Riggs; Yvonne Eberling; Jennifer Troge; Vladimir Grubor; Dan Levy; Pär Lundin; Susanne Månér; Anders Zetterberg; James Hicks; Michael Wigler
Journal:  Genome Res       Date:  2009-11-10       Impact factor: 9.043

3.  MLPAinter for MLPA interpretation: an integrated approach for the analysis, visualisation and data management of Multiplex Ligation-dependent Probe Amplification.

Authors:  Ronald van Eijk; Paul H C Eilers; Remco Natté; Anne-Marie Cleton-Jansen; Hans Morreau; Tom van Wezel; Jan Oosting
Journal:  BMC Bioinformatics       Date:  2010-01-29       Impact factor: 3.169

4.  Genome-wide analysis of Ollier disease: Is it all in the genes?

Authors:  Twinkal C Pansuriya; Jan Oosting; Tibor Krenács; Antonie H M Taminiau; Suzan H M Verdegaal; Luca Sangiorgi; Raf Sciot; Pancras C W Hogendoorn; Karoly Szuhai; Judith V M G Bovée
Journal:  Orphanet J Rare Dis       Date:  2011-01-14       Impact factor: 4.123

5.  Genome haploidisation with chromosome 7 retention in oncocytic follicular thyroid carcinoma.

Authors:  Willem E Corver; Dina Ruano; Karin Weijers; Wietske C E den Hartog; Merlijn P van Nieuwenhuizen; Noel de Miranda; Ronald van Eijk; Anneke Middeldorp; Ekaterina S Jordanova; Jan Oosting; Ellen Kapiteijn; Guido Hovens; Jan Smit; Tom van Wezel; Hans Morreau
Journal:  PLoS One       Date:  2012-06-01       Impact factor: 3.240

6.  Copy number alterations and allelic ratio in relation to recurrence of rectal cancer.

Authors:  Inès J Goossens-Beumer; Jan Oosting; Wim E Corver; Marjolein J F W Janssen; Bart Janssen; Wilbert van Workum; Eliane C M Zeestraten; Cornelis J H van de Velde; Hans Morreau; Peter J K Kuppen; Tom van Wezel
Journal:  BMC Genomics       Date:  2015-06-06       Impact factor: 3.969

7.  Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer.

Authors:  Arantza Fariña Sarasqueta; Giusi Forte; Wim E Corver; Noel F de Miranda; Dina Ruano; Ronald van Eijk; Jan Oosting; Rob A E M Tollenaar; Tom van Wezel; Hans Morreau
Journal:  BMC Cancer       Date:  2013-06-05       Impact factor: 4.430

8.  Deep clonal profiling of formalin fixed paraffin embedded clinical samples.

Authors:  Tara Holley; Elizabeth Lenkiewicz; Lisa Evers; Waibhav Tembe; Christian Ruiz; Joel R Gsponer; Cyrill A Rentsch; Lukas Bubendorf; Mark Stapleton; Doug Amorese; Christophe Legendre; Heather E Cunliffe; Ann E McCullough; Barbara Pockaj; David Craig; John Carpten; Daniel Von Hoff; Christine Iacobuzio-Donahue; Michael T Barrett
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

9.  Loss of heterozygosity and copy number alterations in flow-sorted bulky cervical cancer.

Authors:  Sabrina A H M van den Tillaart; Wim E Corver; Dina Ruano Neto; Natalja T ter Haar; Jelle J Goeman; J Baptist M Z Trimbos; Gertjan J Fleuren; Jan Oosting
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

10.  The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line.

Authors:  Andrew Adey; Joshua N Burton; Jacob O Kitzman; Joseph B Hiatt; Alexandra P Lewis; Beth K Martin; Ruolan Qiu; Choli Lee; Jay Shendure
Journal:  Nature       Date:  2013-08-08       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.